MedPath

The Effectiveness of Probiotics in Neonatal Jaundice

Phase 1
Not yet recruiting
Conditions
Jaundice, Neonatal
Interventions
Drug: Probiotic Formula
Registration Number
NCT06449508
Lead Sponsor
Tanta University
Brief Summary

Hyperbilirubinemia is a prevalent problem in babies that necessitates medical attention. Probiotic administration as adjuvant therapy may have a positive impact on the pathological neonatal unconjugated hyperbilirubinemia.

Detailed Description

Neonatal jaundice is a common health care issue that affects approximately 9% of newborns after birth. The percent of neonates who acquire jaundice in the first week of their birth is about 60%. while the percent of breasted neonates who develop jaundice during the first month of their birth is about 10%.

Phototherapy is the standard therapy for neonates who develop pathological jaundice, as it can alter bilirubin structure and increase its excretion.

Probiotics can also be used for the treatment of jaundice. The efficacy of probiotics depends on their ability to pass across the GIT and cause colonization in the intestinal lumen. Hence, it leads to a decrease in the bacterial growth in the small bowel, a reduction in the function of the gastrointestinal barrier, and a regulation of the immune system of the host.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
44
Inclusion Criteria
  • Neonate suffered from pathological unconjugated hyper-bilirubinemia with Total serum bilirubin (TSB) between 5-15mg/dl and need phototherapy.
Exclusion Criteria
  • neonates who have kernicterus.
  • neonates who have ventilation problem.
  • neonates who have heart failure.
  • -neonates who have asphyxia.
  • neonates who have history of Rh incompatibility

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
probioticsProbiotic Formulawill receive 5 drops of probiotic supplement containing Bacillus clausil spores (Enterogermania amp 2 billion/5 mL) once daily plus phototherapy till discharge.
Primary Outcome Measures
NameTimeMethod
the change in the measured total bilirubin, direct bilirubin, and Indirect Bilirubin.up to 4 weeks
Secondary Outcome Measures
NameTimeMethod
The change in serum concentration of the Human Tumor Necrosis Factor Alpha (TNFa)up to 4weeks
© Copyright 2025. All Rights Reserved by MedPath